Cancer has claimed thousands of lives to-date and caused untold physical, emotional, and financial suffering to its victims and their loved ones. Aging, albeit natural, is also a major medical and social problem that scientists believe can be fixed.
One man is on a mission to overcome these two of humanity’s greatest challenges: Mikhail Blagosklonny.
Who is Mikhail Blagosklonny?
Mikhail Blagosklonny is a scientist, researcher, editor, and professor of oncology. He is one of the leading researchers in the field of oncology, and his research has advanced scientists’ quest to make treatment for cancer and aging. Follow Mikhail on Google Scholar
Education and Occupation Background
Mikhail Blagosklonny holds a Ph.D. in experimental medicine and an M.D. in Internal Medicine. He attended the Pavlov State Medical University of St. Petersburg, where he also held a short stint as a professor.
Mikhail Blagosklonny’s career has mostly revolved around teaching, and he is a renowned professor not only in his institutions but also in his field. Even before he was employed formally, Mikhail Blagosklonny used to volunteer to teach at the Pavlov State Medical University of St. Petersburg. His first formal employment as a professor was in 2002 when he was appointed as the associate professor of medicine at the New York Medical College. Soon after, his expertise soon moved him up the ranks when he was appointed as a senior scientist at Ordway Research Institute in Albany, New York.
Today, Mikhail Blagosklonny is a professor of oncology at the Roswell Park Cancer Institute, a position he has held since 2009. He uses his position at the advanced institute to not only pass on his wisdom but also further his research. He is also a prolific author and editor of research papers. He is the editor-in-chief of several journals including Oncotarget. He is also a member of the Editorial Board of Cell Death ^ Differentiation.
Mikhail Blagosklonny Research on Cancer and Aging
Mikhail Blagosklonny has been instrumental in advancing research on cancer and aging by focusing on Target of Rapamycin (TOR). He realized that TOR is directly involved in aging; reduction in TOR activities is associated with a longer lifespan in mice.
TOR has been identified as a core component of two protein complexes that regulate a variety of cellular processes in the body. These protein complexes, mTOR Complex 1 and mTOR Complex 2 regulate factors such as cell growth, protein synthesis, cell survival, autophagy, cell proliferation, cell motility, and transcription. Visit healingmagic.net to know more about Mikhail
Additionally, mTOR has been identified as a central regulator of physiology and metabolism in mammals. To this end, it senses cellular oxygen, nutrient, and energy levels and regulates them as it deems fit. Hence, supposing that mTOR could be manipulated, then it would be possible to regulate how fast people age; it could also come in handy for targeting specific cancerous cells and protecting the rest from damage associated with treatment.
So far, Mikhail Blagosklonny’s research is not only the most promising but also the safest compared to other proposals. However, the research is still ongoing, and its benefits may not be felt in the near future.